Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
36. |
ECCT/12/11/01 | Prospective Observational Study of Male Circumcision Using the PrePex Device in Routine Clinical Settings in Kenya |
Principal Investigator(s) 1. Robert Bailey 2. Peter Cherutich 3. Walter Obiero 4. Elijah Odoyo June Site(s) in Kenya The Nyanza Reproductive Health Society UNIM clinic in Kisumu with assistance from NRHS’s mobile outreach service providers in Rachuonyo. |
View |
37. |
ECCT/13/05/02 | An open-label randomized controlled trial of the efficacy and safety of Clindamycin plus quinine compared with artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria in western Kenya |
Principal Investigator(s) 1. CHARLES OWUORA OBONYO Site(s) in Kenya Ahero Sub-district Hospital |
View |
38. |
ECCT/21/08/01 | CARES Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa. |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya 1. AMPATH Eldoret (Uasin Gishu county) 2. Aghakhan University (Nairobi City county) 3. Kericho KEMRI WRP CRC site (Kericho county) |
View |
39. |
ECCT/10/09/03 | A0661201 A0661201 AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA |
Principal Investigator(s) 1. Joshua Kimani Site(s) in Kenya University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital |
View |
40. |
ECCT/21/06/05 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR-PHRD THIKA PROJECT |
View |